Market Place
Sourcing Support
Fulcrum stock slumps after muscle disorder drug fails in late-stage study
13 Sep 2024 //
REUTERS
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
14 May 2024 //
BIOPHARMADIVE
Fulcrum Losmapimod FSHD Study Published In Lancet Neurology
08 May 2024 //
GLOBENEWSWIRE
Fulcrum Announces Completion of Enrollment in the Phase 3 Trial of Losmapimod
07 Sep 2023 //
GLOBENEWSWIRE
Fulcrum CEO leaves for new opportunity, company starts search for replacement
04 Jan 2023 //
ENDPTS
Fulcrum Enrolls 1st Patient in Pivotal Global PIII Trial of Losmapimod for FSHD
05 Jul 2022 //
GLOBENEWSWIRE
Fulcrum’s losmapimod fails interim analysis in muscle wasting trial
12 Aug 2020 //
FIERCE BIOTECH
Fulcrum Therapeutics begins trial of muscle disorder drug for COVID-19 patients
24 Jun 2020 //
REUTERS
Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID)
23 Jun 2020 //
GLOBENEWSWIRE
Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19
10 Jun 2020 //
GLOBENEWSWIRE
Fulcrum`s Announces Completion of Enrollment in Ph2b Trial of Losmapimod
26 Feb 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.